Summit Therapeutics Inc. (SMMT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XMEX 
Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying
I'm rating Summit Therapeutics a 'cautious Buy' based on the promising dual-action lung cancer therapy Ivonescimab and significant insider buying. SMMT's Ivonescimab targets non-small cell lung cancer through its dual Anti-PD-1 plus Anti-VEGF mechanism, with the potential to outperform the benchmarks. While there's a lot of uncertainty regarding sales and even more to earnings, valuation suggests significant upside if SMMT captures just 4% market share by 2033.
Summit Therapeutics Inc. (SMMT) Presents at Jefferies London Healthcare Conference 2025 Transcript
Summit Therapeutics Inc. ( SMMT ) Jefferies London Healthcare Conference 2025 November 18, 2025 10:30 AM EST Company Participants Dave Gancarz - Chief Business & Strategy Officer Manmeet Soni - COO, CFO & Director Conference Call Participants Yuxi Dong - Jefferies LLC, Research Division Clara Dong Presentation Yuxi Dong Jefferies LLC, Research Division All right. Good afternoon.
Summit Therapeutics Inc. (SMMT) Presents at UBS Global Healthcare Conference 2025 Transcript
Summit Therapeutics Inc. ( SMMT ) UBS Global Healthcare Conference 2025 November 10, 2025 3:30 PM EST Company Participants Dave Gancarz - Chief Business & Strategy Officer Manmeet Soni - COO, CFO & Director Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division All right, everyone. Thank you for joining us.
Insiders Are Buying These 3 Stocks Hand Over Fist
Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management stands with a company.
SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments
Summit Therapeutics posts a wider Q3 loss as costs surge and investors react to protocol changes in a key ivonescimab study.
Summit's Bold BLA Without Stat-Sig OS: Why I Step Back To Hold
Summit Therapeutics is aggressively pursuing U.S. approval for ivonescimab in NSCLC, despite lacking statistically significant overall survival data. SMMT faces heightened financing risk due to increased trial enrollment and a limited cash runway, with dilution likely if partnerships don't materialize soon. The company's bold BLA strategy and expanded Phase 3 footprint increase binary risk, while regulatory and commercial uncertainties persist without clear OS benefit.
Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential
Summit Therapeutics Inc. (SMMT) is a U.S.-based biopharmaceutical company. It focuses on developing innovative medicines for cancer treatment.
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus
Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to Trade
The mean of analysts' price targets for Summit Therapeutics (SMMT) points to a 63% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Down 36.7% in 4 Weeks, Here's Why Summit Therapeutics (SMMT) Looks Ripe for a Turnaround
Summit Therapeutics (SMMT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Summit Therapeutics: Market Overreaction Creates Opportunity
Summit's ivonescimab showed a 48% reduction in disease progression risk in EGFR-mutant lung cancer — a best-in-class result in a tough-to-treat population. Overall survival data is trending positive but has not yet reached statistical significance; further follow-up may tip the balance. The recent stock sell-off reflects regulatory uncertainty rather than drug failure, creating a potential buying opportunity for long-term investors.
